Назад к подкастам
Decera Clinical Education Oncology Podcast
Podcast ShowПодкастen

Decera Clinical Education Oncology Podcast

ByDecera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

219 эпизодов•0 подписчиков•0 Total Listens

Плейлист эпизодов

50 эпизодов
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
May 14, 2024•—

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Jul 5, 2024•—

Congress to Clinic: Expert Takeaways on Emerging Data for MDS

Congress to Clinic: Expert Takeaways on Emerging Data for AML
Jul 8, 2024•—

Congress to Clinic: Expert Takeaways on Emerging Data for AML

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Jul 9, 2024•—

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
Jul 11, 2024•—

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
Jul 12, 2024•—

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

Current Clinical Practice and NCCN Guidelines for CLL/SLL
Jul 18, 2024•—

Current Clinical Practice and NCCN Guidelines for CLL/SLL

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Jul 22, 2024•—

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Aug 5, 2024•—

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

ROS1-Alterations and Molecular Testing in Advanced NSCLC
Aug 28, 2024•—

ROS1-Alterations and Molecular Testing in Advanced NSCLC

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
Sep 5, 2024•—

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
Sep 6, 2024•—

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
Sep 30, 2024•—

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Oct 1, 2024•—

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations
Oct 16, 2024•—

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
Oct 22, 2024•—

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer
Jan 9, 2025•—

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
Feb 10, 2025•—

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer
Feb 20, 2025•—

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC
Mar 25, 2025•—

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies
Apr 21, 2025•—

The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
Apr 24, 2025•—

The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies
May 5, 2025•—

Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies

Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications
May 16, 2025•—

Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications

Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities
May 29, 2025•—

Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Experts Discuss CELMoDs in Myeloma
Jul 15, 2025•—

Experts Discuss CELMoDs in Myeloma

Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies
Jul 18, 2025•—

Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Jul 18, 2025•—

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
Jul 23, 2025•—

BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
Jul 24, 2025•—

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
Jul 25, 2025•—

Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting
Jul 25, 2025•—

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025
Jul 28, 2025•—

Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
Aug 12, 2025•—

Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
Aug 15, 2025•—

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
Aug 26, 2025•—

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma
Sep 3, 2025•—

Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma

Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients
Sep 4, 2025•—

Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients

Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma
Sep 11, 2025•—

Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options
Oct 13, 2025•—

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options

Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer
Oct 14, 2025•—

Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
Oct 14, 2025•—

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
Oct 28, 2025•—

Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care
Oct 31, 2025•—

Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care

CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
Nov 5, 2025•—

CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
Nov 6, 2025•—

A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
Nov 18, 2025•—

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
Dec 17, 2025•—

PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting

PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
Dec 18, 2025•—

PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
Dec 19, 2025•—

PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

Вам также может понравиться